

✓Thoracic Oncologist at University of California Irvine


Faculty convened at an OncLive Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies. @DrEdKim @MNagasaka @JuliaRotow @peters_solange @DDoroshow @IcahnMountSinai @UCD_Cancer @CHUVLausanne @UCIrvineHealth @cityofhope @DanaFarber @UCLA #lcsm #oncology onclive.com/view/tkd-mutatio…

The PALOMA-2 trial presented by @MNagasaka at #WCLC26 found amivantamab plus lazertinib had clinically meaningful and durable antitumor efficacy for #NSCLC 🫁 Dr Nagasaka spoke with us about the PALOMA-2 trial; see the data and read the article here🔽 bit.ly/4Ajvt5K

At #DAVALung, Dr. @MNagasaka @UCIrvineHealth presented Taletrectinib TRUST-I/II pooled data: TKI-naïve cORR89.8%, DOR 49.7m, PFS 46.1m; TKI-pretreated cORR55.8%, DOR 16.6m, PFS 9.7m. No new safety signals with longer follow-up.


Starting Now: HER2 Kinase Inhibitors and ADCs for HER2/HER3 in NSCLC Moderated by: Dr. Misako Nagasaka @MNagasaka #DAVALung

📸 #ASCO26 Meet 🆙 🌟 @HwakeleeMD @MNagasaka #LCSM @Oncoalert @ASCO @IASLC

Thanks to my colleagues @LudaBazhenovaMD, @MMarmarelis, @FSkoulidis, @JustinGainor, @ryangentzler, @MNagasaka for a WONDERFUL panel discussion and the conference organizers @Idealogy for #TexasLung26!

IDEO Xchange: OptiTROP‑Lung04 - Sac-TMT demonstrated significantly better PFS and OS vs platium-based chemotherapy in post‑EGFR‑TKI NSCLC. How do you rate its clinical impact?

IDEO Xchange: What is your current most common 2L regimen in treatment of patients with EGFRm mNSCLC

IDEO Xchange: What percentage of your new patients in 1L EGFRm mNSCLC still receive osimertinib monotherapy?

IDEO Xchange: How do you currently view the risk/benefit profile for combination regimens in treatment intensification in 1L EGFRm mNSCLC

IDEO Xchange: Given the FLAURA2 exploratory analysis showing that osimertinib plus chemo improved OS across all major poor-prognosis subgroups, how likely are you to use the combination therapy as standard first-line treatment in these populations?

IDEO Xchange: Phase III HARMONi‑6 shows ivonescimab + chemo outperformed tislelizumab + chemo in first‑line squamous NSCLC, with superior PFS and comparable safety. How practice‑changing do you consider these results?

IDEO Xchange: Based on results from BEAMION-1 LUNG-2 cohort 2, which showed a 77% objective response rate and 96% disease control rate in untreated HER2-mutated NSCLC, how likely are you to recommend zongertinib as initial therapy over standard chemotherapy for these patients?

Another option for patients!! On June 11, 2025, the FDA approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive NSCLC. Full prescribing inf for Ibtrozi will be posted on Drugs@FDA.